Rapamycin Inhibits Proliferation of Estrogen-Receptor-Positive Breast Cancer Cells

Journal of Surgical Research

Volumn 138, Issue 1, 2007, Pages 37-44

  Chang, Sharon B ^a,b,c   Miron, Penelope ^a   Miron, Alexander ^a   Iglehart, J Dirk ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

breast cancer; estrogen receptor; rapamycin; tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ESTRADIOL; ESTROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; HUMANS; PHOSPHORYLATION; PROTEIN KINASES; RECEPTORS, ESTROGEN; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TAMOXIFEN; TOR SERINE-THREONINE KINASES;

EID: 33846872568     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2006.07.003     Document Type: Article

References (24)

1. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35 (2003) 7S
2. Ponticelli C. The pleiotropic effects of mTor inhibitors. J Nephrol 17 (2004) 762
3. van der Hoeven B.L., Pires N.M., Warda H.M., et al. Drug-eluting stents: results, promises and problems. Int J Cardiol 99 (2005) 9
4. Monks A., Scudiero D., Skehan P., et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83 (1991) 757
5. Dancey J.E. Clinical development of mammalian target of rapamycin inhibitors. Hematol Oncol Clin North Am 16 (2002) 1101
6. Jacinto E., and Hall M.N. Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4 (2003) 117
7. Hidalgo M., and Rowinsky E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19 (2000) 6680
8. Inoki K., Ouyang H., Li Y., et al. Signaling by target of rapamycin proteins in cell growth control. Microbiol Mol Biol Rev 69 (2005) 79
9. 2005 Cancer Facts and Figures. American Cancer Society.
10. Johnston S.R., Dowsett M., and Smith I.E. Towards a molecular basis for tamoxifen resistance in breast cancer. Ann Oncol 3 (1992) 503
11. Yu K., Toral-Barza L., Discafani C., et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8 (2001) 249
12. Simoncini T., Hafezi-Moghadam A., Brazil D.P., et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407 (2000) 538
13. Sun M., Paciga J.E., Feldman R.I., et al. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 61 (2001) 5985
14. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27
15. Bjornstrom L., and Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and non-genomic actions on target genes. Mol Endocrinol 19 (2005) 833
16. Stoica G.E., Franke T.F., Wellstein A., et al. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol 17 (2003) 818
17. Majumder P.K., Febbo P.G., Bikoff R., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10 (2004) 594
18. Noh W.C., Mondesire W.H., Peng J., et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10 (2004) 1013
19. Podsypanina K., Lee R.T., Politis C., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci USA 98 (2001) 10320
20. Lobenhofer E.K., and Marks J.R. Estrogen-induced mitogenesis of MCF-7 cells does not require the induction of mitogen-activated protein kinase activity. J Steroid Biochem Mol Biol 75 (2000) 11
21. deGraffenried L.A., Friedrichs W.E., Russell D.H., et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10 (2004) 8059
22. Huang S., Bjornsti M.A., and Houghton P.J. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2 (2003) 222
23. Clemons M., Danson S., and Howell A. Tamoxifen ("Nolvadex"): a review. Cancer Treat Rev 28 (2002) 165
24. Awada A., Cardosa F., Fontaine C., et al. A phase Ib study of the mTOR inhibitor RAD001 (everolimus) in combination with letrozole (Femara), investigating safety and pharmacokinetics in patients with advanced breast cancer stable or slowly progressing on letrozole [Abstract]. Breast Cancer Res Treat 88 (2004) S234